Loading
Sight Sciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Jun 2026.
Sight Sciences, Inc.: what insiders have been doing
Sight Sciences, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 15 insiders have disclosed 65 filings since 18 October 2025.
Open-market activity splits into 2 purchases totalling €99k and 29 sales totalling €1.9M; 1 insider sit on the buying side and 6 insiders on the selling side. The totals exclude 1 filing filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 senior executive. Badawi Paul filed the largest sale, €237k, on 5 October 2026, which represents 0.057% of the company's market value.
The latest purchase dates back some time: it was published 129 days ago, on 11 June 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 65 filings, this issuer sits above that mark. Since 2021, the database holds 21 purchases and 78 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 77.4 m USD of revenue and -38.4 m USD of net income.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
201
Thresholds
n/a
Buy Volume
€14M
21 ops. · all time
Sell Volume
€21M
78 ops. · all time
Who traded when
BuySaleDavid Badawi11 sales
Hayden Jeremy B.10 sales
Paul Badawi10 sales
Alison Bauerlein9 sales
Encrantz Staffan7 buys1 sale
Brenton Taylor6 sales
+3 other insiders
Since the insiders bought
- +60.8%Entry US$5.13 · Close 14 Oct 2026 US$8.25
- +116.4%Entry US$3.91 · Close at T+365 US$8.46
- +8.2%Entry US$9.25 · Close at T+365 US$10.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Sight Sciences, Inc. Buy (bullish), based on 5 analysts. Average price target: US$9.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,576 of 24,148 companies
26.7
score / 100
Value19
Quality35
FCF yld-6.6%
Earn yld-8.4%
EV/EBITDA·
ROE-48%
Gross mgn86%
Net mgn-50%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.25
Analyst consensus
5 analystsBuy
US$8.00Target US$9.40(+14%)US$12.00
Income statement
RevenueUS$77.4M
Gross profitUS$66.7M86% margin
EBITDA-US$32.8M-42% margin
Net income-US$38.4M-35.7% margin
Valuation
PER (forward)-19.1x
P/Book8.5x
Beta2.45
Balance sheet & cash
Market capUS$454.5M
Total debtUS$40.8M
Free Cash Flow-US$29.9M
Debt / Equity79%
Profitability & ownership
ROE-48.4%
ROA-10.8%
% insiders19.8%
% institutions52.4%
Last declaration on 5 October 2026
Declarations201 total
2,988 shares@ US$8.8530.0056% mcap2.7% of flowCommon StockSEC:0001193125-26-414283:0
7,208 shares@ US$8.8530.014% mcap21.6% of flowCommon StockSEC:0001193125-26-414277:0
29,653 shares@ US$9.0490.057% mcap13.1% of flowCommon StockSEC:0001193125-26-414272:0
25,260 shares@ US$8.8530.048% mcap16.0% of flowCommon StockSEC:0001193125-26-414281:0
7,797 shares@ US$9.0490.015% mcap13.3% of flowCommon StockSEC:0001193125-26-414275:0
2,988 shares@ US$8.85320.0053% mcap2.8% of flowCommonSEC144:0001959173-26-007229
7,208 shares@ US$8.85320.013% mcap27.6% of flowCommonSEC144:0001959173-26-007224
25,260 shares@ US$8.85320.045% mcap19.0% of flowCommonSEC144:0001959173-26-007241
7,797 shares@ US$9.04910.014% mcap15.3% of flowCommonSEC144:0001959173-26-007196
29,653 shares@ US$9.04910.052% mcap15.1% of flowCommonSEC144:0001959173-26-007198
2,746 shares@ US$9.020.0048% mcap1.4% of flowCommonSEC144:0001959173-26-007194
22,254 shares@ US$9.3490.040% mcap12.0% of flowCommonSEC144:0001959173-26-007157
12,219 shares@ US$8.28760.021% mcap6.5% of flowCommonSEC144:0001959173-26-006765
181,818 shares0Common StockSEC:0001193125-26-355783:0
12,014 shares@ US$8.1440.021% mcap6.3% of flowCommonSEC144:0001959173-26-006121
48,000 shares@ US$8.24750.083% mcap25.4% of flowCommonSEC144:0001959173-26-006045
2,500 shares@ US$8.3050.0044% mcap1.3% of flowCommonSEC144:0001959173-26-005984
16,302 shares@ US$8.17730.028% mcap8.6% of flowCommonSEC144:0001959173-26-005935
20,918 shares@ US$7.92990.035% mcap10.6% of flowCommonSEC144:0001959173-26-005895
7,418 shares@ US$5.50790.0087% mcap10.4% of flowCommonSEC144:0001959173-26-005125
12,733 shares@ US$5.50790.015% mcap4.5% of flowCommonSEC144:0001959173-26-005124
7,418 shares@ US$5.5080.0087% mcap10.4% of flowCommon StockSEC:0001193125-26-296594:0
28,684 shares@ US$5.420.033% mcap10.2% of flowCommon StockSEC:0001193125-26-296589:0
24,184 shares@ US$5.360.028% mcap13.4% of flowCommon StockSEC:0001193125-26-296590:0
2,829 shares@ US$5.420.0033% mcap1.6% of flowCommon StockSEC:0001193125-26-296593:0
25 of 201 declarations
About Sight Sciences, Inc.
Sight Sciences, Inc. (ticker: SGHT) is a United States-based ophthalmic medical technology company listed on the Nasdaq market in the United States. Incorporated in Delaware in 2010 and headquartered in Menlo Park, California, the company has built its identity around interventional eye-care technologies aimed at improving treatment pathways in glaucoma and dry eye disease. Its business model is that of a specialized medtech platform rather than a broad-based medical device franchise.
Sight Sciences operates through two core commercial areas. The Surgical Glaucoma segment is anchored by the OMNI family of products, including OMNI and the newer OMNI Edge system, which are designed for minimally invasive glaucoma surgery (MIGS). These devices are intended to lower intraocular pressure by addressing the eye’s conventional outflow pathways. The Dry Eye segment centers on TearCare, a therapeutic heat-based system used for meibomian gland dysfunction-associated dry eye disease, along with related consumables and accessories. This gives the company two distinct but complementary growth vectors within ophthalmology.
Read moreShow less
From a competitive standpoint, Sight Sciences targets clinically meaningful niches in highly regulated markets. Its positioning depends on product innovation, physician adoption, evidence generation, and reimbursement progress. In glaucoma, the company competes in the MIGS category against larger ophthalmology and medtech players; in dry eye, it faces both procedure-based and drug-based alternatives. Management has consistently emphasized clinical data, peer-reviewed publications, and health-economic support as key levers for adoption and market access. For investors, that means the company’s commercial trajectory is closely linked to how quickly physicians, payers, and hospitals adopt its procedures.
Geographically, Sight Sciences remains primarily U.S.-focused, with the United States as its main commercial market and operational base. Its trademarks and product development have broader reach, but revenue generation is still concentrated domestically. The company does not intend to pay cash dividends and instead reinvests available capital into product development, commercialization, and reimbursement initiatives.
Recent developments have centered on the rollout of OMNI Edge, ongoing efforts to build commercial momentum in MIGS, and the push to establish more favorable reimbursement for TearCare. In 2025, management highlighted these priorities in quarterly updates, and the company’s 2026 full-year results showed a modest recovery in quarterly revenue late in the year alongside lower adjusted operating expenses. For international equity investors, SGHT is best viewed as a Nasdaq-listed U.S. ophthalmic medtech story with meaningful upside potential, but also with sensitivity to reimbursement policy, procedural adoption rates, and execution risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
